{
    "ticker": "SONN",
    "name": "Sonnet BioTherapeutics Holdings, Inc.",
    "description": "Sonnet BioTherapeutics Holdings, Inc. is a biotechnology company focused on the development of innovative immunotherapies for the treatment of cancer and other serious diseases. Founded in 2015, Sonnet is leveraging its proprietary platform to create a new class of therapeutics known as engineered protein therapeutics, which aim to enhance the immune system's ability to target and eliminate tumors. The company's lead product candidate, SON-1010, is designed to harness the body's immune response to fight cancer and is currently being evaluated in clinical trials. Sonnet's approach emphasizes precision medicine and the use of advanced science to create treatments that are both effective and safe. The company is dedicated to improving patient outcomes through innovative research and development, collaborating with leading academic institutions and industry partners to advance its pipeline of therapies. As part of its mission, Sonnet aims to provide patients with new options where there are currently limited treatments available, making significant strides in the field of immuno-oncology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Princeton, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.sonnetbio.com",
    "ceo": "Pankaj Mohan",
    "social_media": {
        "twitter": "https://twitter.com/SonnetBio",
        "linkedin": "https://www.linkedin.com/company/sonnet-biotherapeutics/"
    },
    "investor_relations": "https://investors.sonnetbio.com",
    "key_executives": [
        {
            "name": "Pankaj Mohan",
            "position": "CEO"
        },
        {
            "name": "Michael L. T. Caffrey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immuno-Oncology",
            "products": [
                "SON-1010"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sonnet BioTherapeutics | Innovative Cancer Therapies",
        "meta_description": "Explore Sonnet BioTherapeutics, a leader in immunotherapy development. Learn about SON-1010 and the company's mission to improve cancer treatment options.",
        "keywords": [
            "Sonnet BioTherapeutics",
            "Immunotherapy",
            "Cancer Treatment",
            "SON-1010",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What does Sonnet BioTherapeutics focus on?",
            "answer": "Sonnet BioTherapeutics focuses on developing innovative immunotherapies for cancer and serious diseases."
        },
        {
            "question": "What is SON-1010?",
            "answer": "SON-1010 is Sonnet's lead product candidate designed to enhance the immune response against cancer."
        },
        {
            "question": "Where is Sonnet BioTherapeutics headquartered?",
            "answer": "Sonnet BioTherapeutics is headquartered in Princeton, New Jersey, USA."
        },
        {
            "question": "When was Sonnet BioTherapeutics founded?",
            "answer": "Sonnet BioTherapeutics was founded in 2015."
        },
        {
            "question": "Who is the CEO of Sonnet BioTherapeutics?",
            "answer": "Pankaj Mohan is the CEO of Sonnet BioTherapeutics."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "JNJ",
        "MRNA",
        "NVAX",
        "Pfizer"
    ]
}